Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Martin

Showing results (221-230 of 241) with videos related to

Pageof 25
Sort By:
Nature Genetics|October 24, 2024
Systematic perturbation screens identify regulators of inflammatory macrophage states and a role for TNF mRNA m6A modificationSimone M Haag, Shiqi Xie, Celine Eidenschenk, et al.
Plos Neglected Tropical Diseases|April 14, 2017
The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infectionElizabeth A Nelson, Julie Dyall, Thomas Hoenen, et al.
Science Translational Medicine|October 25, 2023
DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell-mediated antitumor immunityMichael Wichroski, Joseph Benci, Si-Qi Liu, et al.
Journal of Medicinal Chemistry|August 13, 2013
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)Richard A Ward, Mark J Anderton, Susan Ashton, et al.
JCI Insight|July 21, 2020
Severe immunosuppression and not a cytokine storm characterizes COVID-19 infectionsKenneth E Remy, Monty Mazer, David A Striker, et al.
Neuron|March 27, 2026
Microglia-mediated protection against Alzheimer's disease pathology and detrimental effects in white matter revealed by Ptpn6 deletionAinhoa Etxeberria, Seung-Hye Lee, Julia A Kuhn, et al.
Nature Communications|November 10, 2022
Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancersJennifer Cantley, Xiaofen Ye, Emma Rousseau, et al.
Journal of Medicinal Chemistry|June 30, 2012
(1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritisAlexander G Dossetter, Howard Beeley, Jonathan Bowyer, et al.
Journal of Medicinal Chemistry|September 28, 2024
Optimization of Potent, Efficacious, Selective and Blood-Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion MutationsClare Thomson, Erin Braybrooke, Nicola Colclough, et al.
Communications Biology|May 13, 2024
Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTACThomas G Hayhow, Beth Williamson, Mandy Lawson, et al.
Pageof 25

Showing results (221-230 of 241) with videos related to

Sort By:
Pageof 25
Nature Genetics|October 24, 2024
Systematic perturbation screens identify regulators of inflammatory macrophage states and a role for TNF mRNA m6A modificationSimone M Haag, Shiqi Xie, Celine Eidenschenk, et al.
Plos Neglected Tropical Diseases|April 14, 2017
The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infectionElizabeth A Nelson, Julie Dyall, Thomas Hoenen, et al.
Science Translational Medicine|October 25, 2023
DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell-mediated antitumor immunityMichael Wichroski, Joseph Benci, Si-Qi Liu, et al.
Journal of Medicinal Chemistry|August 13, 2013
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)Richard A Ward, Mark J Anderton, Susan Ashton, et al.
JCI Insight|July 21, 2020
Severe immunosuppression and not a cytokine storm characterizes COVID-19 infectionsKenneth E Remy, Monty Mazer, David A Striker, et al.
Neuron|March 27, 2026
Microglia-mediated protection against Alzheimer's disease pathology and detrimental effects in white matter revealed by Ptpn6 deletionAinhoa Etxeberria, Seung-Hye Lee, Julia A Kuhn, et al.
Nature Communications|November 10, 2022
Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancersJennifer Cantley, Xiaofen Ye, Emma Rousseau, et al.
Journal of Medicinal Chemistry|June 30, 2012
(1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritisAlexander G Dossetter, Howard Beeley, Jonathan Bowyer, et al.
Journal of Medicinal Chemistry|September 28, 2024
Optimization of Potent, Efficacious, Selective and Blood-Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion MutationsClare Thomson, Erin Braybrooke, Nicola Colclough, et al.
Communications Biology|May 13, 2024
Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTACThomas G Hayhow, Beth Williamson, Mandy Lawson, et al.
Pageof 25